Aurobindo Pharma gets USFDA warning letter
  • WebDesk BTVI
  • Jun 21 2019

Aurobindo Pharma has received a letter of warning from US drugs regulator body USFDA for Unit 11 of its Srikakulam API facility. The USFDA had in May 2019 classified three of its units – units 1, 9 and 11 under OAI. 60-65% of the pharma firm’s US revenues are backward integrated to the existing 11 API facilities. After an inspection by USFDA in February, Unit 11 had received 3 observations.